Table 2.
TMA based immunohistochemical findings in fibro-osseous lesions of the jaws.
| Immunohistochemical Findings | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cases | Ki-67 | CK AE1/AE3 | Beta-Catenin | E-Cadherin | N-Cadherin | OB-Cadherin | P-Cadherin | P-Runx2 | ||
| Cell Count/HPF ° | Score | Sub-Cellular Localization | Score | Nuclear Score |
Score | Score | Score | Score | Score | |
| 1 | 6 | 0 | C | 3+Os | 0 | 0 | 3+Os Fbs | 0 | 3+ | 3+Os, Fbs |
| 2 | 0 | 0 | CM | 3+Os | 0 | 0 | 3+Os Octs | 1+ | 0 | 3+Os, Fbs |
| 3 | 4 | 0 | 0 | 0 | 0 | 3+ | 0 | 0 | 3+Os, Fbs | |
| 4 | 1 | 0 | C | 2+Os | 0 | 0 | 2+Os; 0 Fbs | 0 | 0 | 0 |
| 5 | 3 | 0 | C | 3+Os Fbs | 0 | 0 | 2+Os Fbs | 0 | 1+ | 3+Os, Fbs |
| 6 | 0 | - | 0 | 0 | 0 | 1+ | 0 | 0 | 2+Os, Fbs | |
| 7 | 0 | - | 0 | 0 | 0 | 3+ | 0 | 0 | 0 | |
| 8 | 5 | 0 | CN | 3+Os Fbs | 3+ | 0 | 3+ | 0 | 0 | 3+Os, Fbs |
| 9 | 0 | 1+ | C | 1+ | 0 | 0 | 1+ | 0 | 0 | 2+Os, Fbs |
| Controls | - | |||||||||
| 10 | 4 | 0 | M | 0 | 0 | 0 | 0 | 0 | 1+ | |
| 11 | 2 | 0 | - | 0 | 0 | 1+ | 0 | 0 | 0 | 1+ |
| 12 | 4 | 0 | M | 0 | 0 | 0 | 0 | 0 | 1+ | |
| 13 | 5 | 0 | M | 1+ | 0 | 1+ | NV | 0 | 0 | 1+ |
| 14 | 6 | 0 | - | 0 | 0 | 0 | 2+Fbs | 0 | 0 | 2+ |
| 15 | 0 | 0 | M | 1+ | 0 | 1+ | 1+ | 2+ | 1+ | 1+ |
| 16 | 4 | 0 | M | 1+ | 0 | 0 | 2+ | 3+ | 1+Os | 2+ |
Legend: CK, cytokeratin AE1/AE3; Ki-67, proliferation index as evaluated by Mib-1 Ab. M, only membranous staining; C, only cytoplasmic; C-M, mixed membranous and cytoplasmic localization of beta-catenin, main cytoplasmic; C-N, mixed cytoplasmic and nuclear localization of beta-catenin, main cytoplasmic. Os, osteoblasts. Octs, osteocytes. Fbs, fibroblastoid appearing osteoblastic precursors. NV, non-valuable. Score, mean percentage of immune-labeled cells as evaluated by optical microscope and scored semi-quantitatively: 0, negative; 1+, <25; 2+, 25–50; 3+, 50–75; 4+, >75. ° Count of immunostained cells in 4 high power field (HPF).